Cargando…

Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer

The aim of this study was to prospectively assess 5-year health-related quality of life (HRQOL) of patients treated with carbon ion radiotherapy (C-ion RT) for clinically localized prostate cancer. A total of 417 patients received carbon ion radiotherapy at a total dose of 63–66 Gray-equivalents (Gy...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Katsuya, Tsuji, Hiroshi, Nomiya, Takuma, Katoh, Hiroyuki, Ishikawa, Hitoshi, Kamada, Tadashi, Wakatsuki, Masaru, Akakura, Koichiro, Shimazaki, Jun, Aoyama, Hidefumi, Tsujii, Hirohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439371/
https://www.ncbi.nlm.nih.gov/pubmed/28043947
http://dx.doi.org/10.1093/jrr/rrw122
_version_ 1783237935484633088
author Maruyama, Katsuya
Tsuji, Hiroshi
Nomiya, Takuma
Katoh, Hiroyuki
Ishikawa, Hitoshi
Kamada, Tadashi
Wakatsuki, Masaru
Akakura, Koichiro
Shimazaki, Jun
Aoyama, Hidefumi
Tsujii, Hirohiko
author_facet Maruyama, Katsuya
Tsuji, Hiroshi
Nomiya, Takuma
Katoh, Hiroyuki
Ishikawa, Hitoshi
Kamada, Tadashi
Wakatsuki, Masaru
Akakura, Koichiro
Shimazaki, Jun
Aoyama, Hidefumi
Tsujii, Hirohiko
author_sort Maruyama, Katsuya
collection PubMed
description The aim of this study was to prospectively assess 5-year health-related quality of life (HRQOL) of patients treated with carbon ion radiotherapy (C-ion RT) for clinically localized prostate cancer. A total of 417 patients received carbon ion radiotherapy at a total dose of 63–66 Gray-equivalents (GyE) in 20 fractions over 5 weeks, and neoadjuvant and adjuvant androgen deprivation therapy (ADT) were administered for intermediate and high-risk patients. A HRQOL assessment was performed at five time points (immediately before the initiation of C-ion RT, immediately after, and at 12, 36 and 60 months after completion of C-ion RT) using Functional Assessment of Cancer Therapy (FACT) questionnaires. FACT-G and FACT-P scores were significantly decreased; however, the absolute change after 60 months was minimal. The transient decreases in the Trial Outcome Index (TOI) score returned to their baseline levels. Use of ADT, presence of adverse events, and biochemical failure were related to lower scores. Scores of subdomains of FACT instruments indicated characteristic changes. The pattern of HRQOL change after C-ion RT was similar to that of other modalities. Further controlled studies focusing on a HRQOL in patients with prostate cancer are warranted.
format Online
Article
Text
id pubmed-5439371
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54393712017-05-25 Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer Maruyama, Katsuya Tsuji, Hiroshi Nomiya, Takuma Katoh, Hiroyuki Ishikawa, Hitoshi Kamada, Tadashi Wakatsuki, Masaru Akakura, Koichiro Shimazaki, Jun Aoyama, Hidefumi Tsujii, Hirohiko J Radiat Res Oncology The aim of this study was to prospectively assess 5-year health-related quality of life (HRQOL) of patients treated with carbon ion radiotherapy (C-ion RT) for clinically localized prostate cancer. A total of 417 patients received carbon ion radiotherapy at a total dose of 63–66 Gray-equivalents (GyE) in 20 fractions over 5 weeks, and neoadjuvant and adjuvant androgen deprivation therapy (ADT) were administered for intermediate and high-risk patients. A HRQOL assessment was performed at five time points (immediately before the initiation of C-ion RT, immediately after, and at 12, 36 and 60 months after completion of C-ion RT) using Functional Assessment of Cancer Therapy (FACT) questionnaires. FACT-G and FACT-P scores were significantly decreased; however, the absolute change after 60 months was minimal. The transient decreases in the Trial Outcome Index (TOI) score returned to their baseline levels. Use of ADT, presence of adverse events, and biochemical failure were related to lower scores. Scores of subdomains of FACT instruments indicated characteristic changes. The pattern of HRQOL change after C-ion RT was similar to that of other modalities. Further controlled studies focusing on a HRQOL in patients with prostate cancer are warranted. Oxford University Press 2017-03 2017-01-11 /pmc/articles/PMC5439371/ /pubmed/28043947 http://dx.doi.org/10.1093/jrr/rrw122 Text en © The Author 2017. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oncology
Maruyama, Katsuya
Tsuji, Hiroshi
Nomiya, Takuma
Katoh, Hiroyuki
Ishikawa, Hitoshi
Kamada, Tadashi
Wakatsuki, Masaru
Akakura, Koichiro
Shimazaki, Jun
Aoyama, Hidefumi
Tsujii, Hirohiko
Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
title Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
title_full Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
title_fullStr Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
title_full_unstemmed Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
title_short Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
title_sort five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439371/
https://www.ncbi.nlm.nih.gov/pubmed/28043947
http://dx.doi.org/10.1093/jrr/rrw122
work_keys_str_mv AT maruyamakatsuya fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT tsujihiroshi fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT nomiyatakuma fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT katohhiroyuki fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT ishikawahitoshi fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT kamadatadashi fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT wakatsukimasaru fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT akakurakoichiro fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT shimazakijun fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT aoyamahidefumi fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT tsujiihirohiko fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer
AT fiveyearqualityoflifeassessmentaftercarbonionradiotherapyforprostatecancer